Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Amendment to Stock Incentive Plan



On May 20, 2021, Emergent BioSolutions Inc. (the "Company") held its 2021 annual
meeting of stockholders (the "Annual Meeting"). At the Annual Meeting, the
Company's stockholders approved the Emergent BioSolutions Inc. Amended and
Restated Stock Incentive Plan (the "Amended Plan"). The Board of Directors
previously adopted the Amended Plan on March 18, 2021, subject to stockholder
approval.

The Amended Plan increases the number of shares of the Company's common stock
available for issuance under the plan by 3,500,000 shares, subject to adjustment
in the event of stock splits and other similar events and removes references to
Section 162(m) of the Internal Revenue Code of 1986, as amended.

The description above is a summary of certain provisions contained in the
Amended Plan and does not purport to be complete. A more fulsome description of
the terms and conditions of the Amended Plan is set forth in the Company's
definitive proxy statement on Schedule 14A related to the Annual Meeting, filed
on April 9, 2021 (the "Proxy Statement"). Such descriptions are qualified in
their entirety by reference to the Amended Plan, a blacklined copy of which is
attached as Appendix A to the Proxy Statement.

Departure of Director

Dr. Sue Bailey completed her term as a director of the Company and did not stand for reelection when her term as a Class III director expired at the Annual Meeting.

Item 5.07 Submission of Matters to a Vote of Security Holders.



As noted above, the Annual Meeting was held on May 20, 2021. A total of
49,582,397 shares of the Company's common stock were present or represented by
proxy, which represented approximately 92.54% of the Company's 53,576,925 shares
of common stock that were outstanding and entitled to vote at the Annual Meeting
as of the record date of March 25, 2021. Stockholders considered the four
proposals outlined below, each of which is described in more detail in the Proxy
Statement.

Proposal 1. To elect three Class III directors to hold office for a term
expiring at our 2024 annual meeting of stockholders and until their respective
successors are duly elected and qualified. All director nominees were elected.
The voting results were as follows:

  Director Nominee        For         Against     Abstaining     Broker Non-Votes
Robert Kramer          46,009,428    1,220,174     115,345          2,237,450
Jerome Hauer           43,425,265    3,804,300     115,382          2,237,450
Marvin White           38,135,285    8,490,961     718,701          2,237,450



Proposal 2. To ratify the appointment by the Audit Committee of Ernst & Young
LLP as our Independent Registered Public Accounting Firm for the fiscal year
ending December 31, 2021. Proposal 2 was approved. The voting results were as
follows:

     For         Against     Abstaining     Broker Non-Votes
  49,001,106     538,419       42,872             N/A

Proposal 3. To approve, on an advisory basis, the compensation of our named executive officers. Proposal 3 was approved. The voting results were as follows:



     For         Against     Abstaining     Broker Non-Votes
  45,345,745    1,957,145      42,057          2,237,450

Proposal 4. To approve an amendment to our stock incentive plan. Proposal 4 was approved. The voting results were as follows:

--------------------------------------------------------------------------------

For Against Abstaining Broker Non-Votes

44,092,331 3,208,764 43,852 2,237,450

Item 7.01 Regulation FD Disclosure.

On May 20, 2021, Company management delivered a presentation at the Annual Meeting. A copy of the presentation is being furnished as Exhibit 99 hereto.

Item 9.01. Financial Statements and Exhibits.



(d)  Exhibits.

Exhibit No.                                                  Description
          99                    Annual Meeting Presentation.
          101                 Emergent BioSolutions Inc. Current Report on

Form 8-K, dated May 20, 2021,


                              formatted in XBRL (Extensible Business

Reporting Language): Cover Page.


                              The instance document does not appear in the

Interactive Data File because


                              its XBRL tags are embedded within the Inline

XBRL document.


          104                 Cover Page Interactive Data File (formatted

as Inline XBRL and contained


                              in Exhibit 101).

© Edgar Online, source Glimpses